WNY Asset Management LLC Takes $800,000 Position in Pfizer Inc. $PFE

WNY Asset Management LLC acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the 2nd quarter, Holdings Channel reports. The fund acquired 33,220 shares of the biopharmaceutical company’s stock, valued at approximately $800,000.

A number of other hedge funds have also modified their holdings of PFE. BlackRock Inc. raised its holdings in shares of Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares during the last quarter. State Street Corp boosted its holdings in Pfizer by 0.5% during the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after purchasing an additional 1,357,756 shares during the last quarter. Geode Capital Management LLC grew its position in Pfizer by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after purchasing an additional 1,184,728 shares in the last quarter. Morgan Stanley grew its position in Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Finally, Norges Bank acquired a new stake in Pfizer in the 4th quarter valued at $1,830,986,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent research reports. BMO Capital Markets reduced their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Monday, July 6th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Finally, HSBC lowered Pfizer from a “buy” rating to a “hold” rating and lowered their price target for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Stock Down 1.0%

Shares of PFE stock opened at $28.00 on Friday. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $28.75. The stock has a market cap of $159.62 billion, a price-to-earnings ratio of 36.85 and a beta of 0.34. The firm’s 50-day moving average is $25.49 and its 200-day moving average is $26.29. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is currently 226.32%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.